The purpose of the present study was to evaluate the potential usefulness of tubulin inhibitors when complexed with hydroxypropyl-â-cyclodextrin (ÇPâCD) against a range of protozoan parasites. This approach involved investigations into the complexation of these drugs with ÇPâCD, and subsequent investigations of these drugs and their complexes in regard to cytotoxicity, pharmacokinetics, in vitro efficacy against Giardia, Cryptosporidium and rodent malaria (Plasmodium chabaudi), and their in vivo efficacy against Giardia and malaria. Albendazole (ABZ) is a benzimidazole carbamate with a broad anti-parasite spectrum, while the dinitroanilines trifluralin (TF) and oryzalin (OZ) have recently been found to exhibit activity against certain parasites. All three compounds are microtubule antagonists in either nematodes or weeds and have poor aqueous solubility, with the solubility of ABZ and OZ dependent on pH. Cyclodextrins (CD) have a hydrophobic cavity that allows them to form inclusion complexes with hydrophobic drugs, resulting in increased drug aqueous solubility, and often, improved drug dissolution and bioavailability. Thus the complexation of these drugs with ÇPâCD was investigated. All three compounds exhibited type AL phase solubility diagrams with ÇPâCD complexation, with additional increases in ABZ and OZ solubility achieved through the manipulation of temperature and pH. OZ displayed a stronger interaction with ÇPâCD when ionised over its neutral form. However, insufficient concentrations of the TF/ÇPâCD complex were achieved for drug efficacy studies. The cytotoxicity of the drugs and their complexes was assessed using the assay kit Cytotox 96 with human carcinoma cells. This is a colourimetric assay that measures lactate dehydrogenase release as a consequence of compromised cellular and membrane integrity. Both ABZ and OZ are cytotoxic to rapidly proliferating and differentiating cells but are not cytotoxic to cells in the stationary phase. Complexation did not affect drug cytotoxicity. In pharmacokinetic studies, complexation improved ABZ (and metabolites) bioavailability, but had no significant affect on OZ bioavailability. In vitro drug assessment studies found ABZ to be highly effective against Giardia, and effectiveagainst Cryptosporidium and malaria. OZ on the other hand exhibited no activity against Giardia, but was effective against Cryptosporidium and malaria. Complexation did not improve the antiprotozoal efficacy of either ABZ or OZ. In particular, excess ÇPâCD decreased the antigiardial effects of ABZ, possibly due to competitive complex formation. In addition, complexation did not improve the antiprotozoal effects of ABZ in vivo. However, the cytotoxic effect of the ABZ/ÇPâCD complex was more evident in the treatment of malaria in vivo, resulting in increased anaemia and suppression in weight gain, due to the improved bioavailability of ABZ and metabolites. ÇPâCD alone was found to be cytotoxic at greater than 2.5%, and inhibited Giardia both in vitro and in vivo at greater than 1% and 2% respectively. This was attributed to membrane disruption caused by the dissolution and removal of membrane components. In comparison, malaria grew better in the presence of ÇPâCD in vitro, with no detrimental effect observed at up to 8% ÇPâCD. This was attributed to either the increased solubilization of a necessary media component, or the complexation and removal of an inhibitory compound from the cultivation medium. Therefore ÇPâCD complexation did not improve the antiprotozoal activity of the tubulin antagonists ABZ and OZ. However, the results of the pharmacokinetic studies suggest that anthelmintic activity of ABZ, particularly against systemic infections, may be improved with oral administration of the ABZ/ÇPâCD complex. In addition, the antiparasitic activity of ÇPâCD alone may be promising, especially against intestinal infections. Finally, the improved in vitro cultivation of P. chabaudi in the presence of ÇPâCD presents a promising approach to its potential long term cultivation.

This dissertation describes an introduction, background and research progress in the areas of multitargeted single agents and tubulin inhibitors in cancer chemotherapy and selective Toxoplasma gondii TS inhibitors for the treatment of toxoplasmosis.<br> Tubulin inhibitors are important antitumor agents that disrupt microtubule dynamics. Thymidylate synthase (TS) inhibitors prevent cell division by interfering with de novo thymidylate synthesis. Antiangiogenic agents target tumor angiogenesis crucial for tumor growth and metastasis. Under normal circumstances, angiogenesis is typically limited to tumor cells and is mediated by receptor tyrosine kinases (RTKs). Combination chemotherapies of RTK inhibitors with cytotoxic agents that target either TS or tubulin have shown significant promise and several preclinical and clinical studies with such combinations are in progress. Multitargeted single agents with dual antiangiogenic and cytotoxic mechanisms could avoid the major limitations associated with cancer chemotherapy: multidrug resistance and dose limiting toxicities. This dissertation focuses on the design and synthesis of pyrimido[4,5-b]indoles and furo[2,3-d]pyrimidines as potential single agents with dual antiangiogenic and cytotoxic activities. These efforts led to the identification of structural features that are necessary for inhibition of RTKs and/or tubulin polymerization. Novel synthetic strategies were developed for efficient synthesis of 2,4-diamino-5-thioaryl-pyrimido[4,5-b]indoles and 4-anilino-5-methyl-furo[2,3-d]pyrimidines.<br> Taxanes and vinca alkaloids are widely used tubulin inhibitors in cancer chemotherapy. However, their clinical use is compromised by two major mechanisms of drug resistance: the overexpression of Pgp and bIII-tubulin. This dissertation describes the design and synthesis of pyrimido[4,5-b]indoles as tubulin inhibitors that circumvent Pgp and bIII-tubulin mediated resistance. This work identified the structural features crucial for tubulin inhibition for the pyrimido[4,5-b]indole scaffold.<br> Infection by Toxoplasma gondii can lead to toxoplasmosis in immune compromised patients such as organ transplant, cancer and AIDS patients. Current therapy involving combination of sulfadiazine and pyrimethamine is limited by drug resistance and treatment failures. The thymidylate synthase‒dihydrofolate reductase enzyme is important for thymidylate synthesis in T. gondii, and hence can be targeted to treat T. gondii infection. TS is highly conserved across species and selectivity for tgTS over human TS is significantly more challenging. The present work provides an efficient synthesis of 2-diamino-4-oxo-5-thioaryl-pyrimido[4,5-b]indoles as selective tgTS inhibitors. / Mylan School of Pharmacy and the Graduate School of Pharmaceutical Sciences; / Medicinal Chemistry / PhD; / Dissertation;

En 2015, on estime le nombre de nouveaux cas de cancer à plus de 385000 et le nombre de décès à 149500. Ces chiffres, plus élevés chez l'homme que chez la femme, connaissent ces dernières années une nette recrudescence chez les patients de sexe féminin. Globalement, la principale difficulté pour lutter contre les cancers se situe dans la capacité à les détecter avant qu'ils ne métastasent et dans les nombreux phénomènes de résistance aux traitements chimiothérapeutiques.De par son implication dans la croissance des cellules cancéreuses, le réseau vasculaire tumorale représente une cible intéressante ainsi qu'une alternative prometteuse aux traitements actuels. Ainsi, la classe de composés qualifiés de VDAs (pour « Vascular Disrupting Agents ») visent les cellules endothéliales ainsi que les péricytes, provoquant ainsi des phénomènes d'ischémie et de nécrose cellulaire. Un exemple de ce type de composés n'est autre que la Combrétastatine A-4 (ou CA-4), qui est un composé naturel extrait d'un arbuste sud-africain, le Combretum caffrum. Cette molécule a été pour la première fois étudiée par G.R. Pettit en 1989 qui a alors démontré qu'elle pouvait inhiber très efficacement la polymérisation des dimères α et β de tubuline en microtubules, résultant alors en la non-formation du cytosquelette, et l'apoptose de la cellule. Le développement de nouveaux analogues de la CA-4 s'avère crucial car ce composé dispose non seulement d'une solubilité réduite mais peut aussi être instable lorsqu'il est administré. Le travail effectué lors de cette thèse a donc consisté dans un premier temps en la synthèse de nouveaux dérivés de la CA-4 en remplaçant le noyau B par différents hétérocycles et en effectuant plusieurs pharmacomodulations ; ces derniers étant alors évalués pour leurs propriétés inhibitrices de la polymérisation de la tubuline et antiprolifératives. Avec plus de 24 millions de personnes touchées dans le monde, les pathologies neurodégénératives représentent un problème majeur de santé publique. Il est également très important de considérer l'incidence future de ces pathologies, et on estime à plus de 42 millions le nombre de personnes qui seraient atteintes par ce fléau d'ici à 2020. La famille des protéines kinases DYRK a fait l'objet ces dernières années d'une attention toute particulière de par son implication dans de nombreux phénomènes physiologiques et notamment au niveau des phases primaires du développement du système nerveux central. Plus spécifiquement, les kinases DYRK1A et DYRK1B ont été étudiées de par leurs implications dans de nombreux cancers (notamment le glioblastome) et certaines pathologies neurocérébrales. Le dérèglement de l'expression de ces protéines pourrait être la cause de retards mentaux, du développement de la maladie d'Alzheimer, de la trisomie 21, ainsi que de phénomènes de résistance. Nous avons identifié au sein de notre laboratoire une molécule inhibant ces 2 kinases. Initialement développé dans le but d'inhiber la protéine kinase CK2 (caséine kinase 2), notre composé a montré une activité inhibitrice et une sélectivité sur DYRK1A et DYRK1B. De par son activité, cette molécule est aujourd'hui notre composé « hit » et nous visons, à travers les travaux de cette thèse, la synthèse de multiples analogues dans le but d'améliorer l'activité initiale mais aussi sa spécificité sur DYRK1A ou sur DYRKB. Dans cette optique, nous avons réalisé différentes pharmacomodulations de nos composés dits « indénobenzo[b]thiophènes » et étudier les effets de tels composés sur DYRK1A, DYRK1B, DYRK2 mais aussi sur CK2. Ceci nous a permis d'affiner nos connaissances vis-à-vis des kinases de type DYRK et de sélectionner les molécules les plus prometteuses afin de (i) réaliser une étude autour de leurs caractéristiques physico-chimiques (Log P, solubilités dans différents solvants), (ii) d'analyser leurs comportements au niveau de la barrière hémato-encéphalique (BHE) et (iii) de réaliser des nano-encapsulations / Up to now, cancer is the second deadliest pathology in the World and is still considered as one of the most challenging public health issue. Globally, it has been assessed to be the main pathologic cause of death by the World Health Organization. This bad prognosis is partly due to the ability of cancer cells to give metastases but also to resistances phenomenon impeding drastically the effect of chemotherapeutic and radiotherapeutic treatments. As a consequence, there is currently a critical lack of effective treatments which would completely eradicate tumor cells, with minimal side effects. In spite of some difficulties in this competitive research area, the discovery of cancer therapeutics remains stimulating and we aim to achieve the synthesis of novel anticancer agents.Given its pivotal role in tumor growth and survival, the tumor vasculature represents an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new blood vessels, the class of vascular disrupting agents (VDAs) targets endothelial cells and pericytes of the already established tumor vasculature, resulting in tumor ischemia and necrosis. A striking example of VDA is the combretastatin A-4, also known as CA-4, which was originally isolated from the bark of the South African willow tree Combretum caffrum by the American scientist G.R. Pettit in 1989. These products demonstrated to be efficient against a wide array of cancers such as breast, colon, lung or ovarian cell lines. New CA-4 analogs containing different heterocycles instead of the hydroxymethoxy substituted pharmacomodulable B ring were prepared and evaluated for their in cellulo tubulin polymerization inhibition and antiproliferative activities. In the other hand, tumor cell survival is a complex process which remains poorly understood. As part of the survival machinery, chemoresistances and DNA repairs are central elements regulated by a prosurvival/proapoptotic signal balance. Protein kinases are known to be directly involved in this signal transmission through molecular interactions. As such, DYRK kinases and most specifically DYRK1A/1B, were part of numerous recent studies due to their involvement in cancer and other pathologies. DYRK1B (also called Mirk kinase) is an ubiquitous kinase which was proved to be over-expressed in many cancers such as pancreatic, ovarian or colon. Its involvement as a regulator of DNA repair and tumor cell survival was assessed, phosphorylating specifically serine, threonine and tyrosine residues. Also, another closely related isoform known as DYRK1A, was mapped in the Down syndrome critical region located itself on chromosome 21. Interestingly, this kinase was not only uncovered to play a fundamental role in glioblastomas survival but was also associated with abnormal brain development in early stages and mental retardations. Particularly, DYRK1A was found to hyperphosphorylate microtubule-associated tau protein, resulting into genesis of neurofibrillary tangles. As a consequence, DYRK1A has become one of the most targeted proteins in order to improve cognitive impairment of patients suffering from Down syndrome or Alzheimer’s disease. Initially designed to target protein kinase CK2, one of our molecules was also tested on DYRK kinases. This compound exhibited a strong activity against DYRK1A/DYRK1B whilst being inactive on other protein kinases. Consequently, it was considered as our hit compound and (i) we synthetized derivatives as dual or single inhibitors of DYRK1A/DYRK1B, (ii) evaluated their biological activities (with emphasis on the blood brain barrier), and (iii) finally synthesized nanoparticles loaded with our inhibitors

La combrétastatine A-4 est un produit naturel isolé d'un arbuste africain Combretum caffrum et qui possède de très intéressantes propriétés biologiques: inhibition de la polymérisation de la tubuline et propriétés antiprolifératives auprès de nombreuses cellules tumorales. Malheureusement, ce produit possède de propriétés pharmacocinétiques non optimales qui limitent son application clinique. Par conséquent de nombreux dérivés synthétiques ont été testés et parmi ceux-ci, l'isocombrétastatine A-4 (isoCA-4). Dans notre travail de thèse, nous avons donc synthétisé des analogues de l'isoCA-4 dont un des cycles aromatiques a été remplacé par des hétérocycles thiophènes et benzothiophènes diversement substitués. Certains de ces produits ont montré des activités du même ordre que la colchicine, substance de référence sur la polymérisation de la tubuline, et sur la prolifération de cellules mélanocytaires IC8. Les composés présentant une structure benzo[b]thiophène montrent une meilleure activité que ceux ayant une simple structure thiophène. De plus, les composés portant une chaine latérale en position 2 montrent une activité supérieure à ceux substitués en position 3.D'autre part, les stuctures indénoindoles sont connues comme étant de puissants inhibiteurs de la caséine kinase 2 (CK2), celle-ci joue un rôle important dans de nombreux processus cellulaires. A partir de cette structure indénoindole et, en utilisant une stratégie proche de celle utilisée pour la série précédente (par introduction d'un atome d'iode en position ortho et cyclisation pallado-catalysée), nous avons synthétisé des analogues indénohétérocycliquesen remplaçant le noyau indolepar des noyauxthiophèneetbenzo[b]thiophène. L'activité inhibitrice de ces dérivés vis-à-vis de la CK2 a été évaluée et l'un de ces composés a montré une forte activité / Isocombretastatin A-4 (isoCA-4), a modified combretastatin A-4 (CA-4), was recently discovered known as a strong activity compound to inhibit tubulin polymerization. The vinyl derivatives opened a new series which is hardly exploited. Based on the structure of isoCA-4, we synthesized isoheterocycles series by replacing the B-ring of isoCA-4 by thiophene and benzo[b]thiophene derivatives. These two series were evaluated in their ability to inhibit tubulin assembly. The benzo[b]thiophene derivativesshowed better activity than thiophene derivatives, the binding position 2 of benzo[b]thiophene showed higher activity than position 3. Indenoindoles was known as a potent series to inhibit casein kinase 2 which plays important role in many processes in cell. Based on the structure of indenoindole, we synthesized indenoheterocycles by replacing indole by thiophene and benzo[b]thiophene derivatives. These two series were evaluated in their ability to inhibit CK2. One of the compoundsshowed high activity